Severe mold fungal infections in critically ill patients with COVID-19

References

• Cag Y, Erdem H, Gormez A et al. Anxiety among front-line health-care workers supporting patients with COVID-19: a global survey. Gen Hosp. Psychiatry 68, 90–96 (2021).
   PubMed Web of Science ®Google Scholar
• Bekker Mortensen C, Zachodnik J, FjordbakCaspersen S, Geisler A. Healthcare professionals’ experiences during the initial stage of the COVID-19 pandemic in the intensive care unit: a qualitative study. Intensive Crit. Care Nurs. 68, 103130 (2021).
   PubMed Web of Science ®Google Scholar
• Jansson M, Liao X, Rello J. Strengthening ICU health security for a coronavirus epidemic. Intensive Crit. Care Nurs. 57, 102812 (2021).
   Web of Science ®Google Scholar
• Blot S, Ruppé E, Harbarth S et al. Healthcare-associated infections in adult intensive care unit patients: changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit. Care Nurs. 70, 103227 (2022).
   PubMed Web of Science ®Google Scholar
• Conway Morris A, Kohler K, De Corte T et al. coinfection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data set. Crit. Care 26, 236 (2022).
   PubMed Web of Science ®Google Scholar
• Kuchi Bhotla H, Balasubramanian B, Meyyazhagan A et al. Opportunistic mycoses in COVID-19 patients/survivors: epidemic inside a pandemic. J. Infect. Public Health 14(11), 1720–1726 (2021).
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Sprute R et al. COVID-19-associated fungal infections. Nat. Microbiol. 7, 1127–1140 (2022).
   PubMed Web of Science ®Google Scholar
• Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect. Dis. 17(11), e357–e366 (2017).
   PubMed Web of Science ®Google Scholar
• Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Curr. Opin. Crit. Care 25(5), 430–437 (2019).
   PubMed Web of Science ®Google Scholar
• Dewi IMW, Janssen NAF, Rosati D et al. Invasive pulmonary aspergillosis associated with viral pneumonitis. Curr. Opin. Microbiol. 62, 21–27 (2021).
   PubMed Web of Science ®Google Scholar
• Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Curr. Opin. Infect Dis. 31(6), 471–480 (2018).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Bruggemann RJM, Azoulay E et al. Taskforce report on the diagnosis and clinical management of COVID-19-associated pulmonary aspergillosis. Intensive Care Med. 47(8), 819–834 (2021).
   PubMed Web of Science ®Google Scholar
• Gangneux J-P, Bougnoux M-E, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J. Mycol. Med. 30(2), 100971 (2020).
   PubMed Web of Science ®Google Scholar
• Iqbal A, Ramzan M, Akhtar A, Ahtesham A, Aslam S, Khalid J. COVID-associated pulmonary aspergillosis and its related outcomes: a single-center prospective observational study. Cureus 13(8), e16982 (2021).
   PubMed Web of Science ®Google Scholar
• Kariyawasam RM, Dingle TC, Kula BE, Vandermeer B, Sligl WI, Schwartz IS. Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis. Clin. Microbiol. Infect. 28(7), 920–927 (2022).
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Pascale R, Cricca M et al. PREDICO study group. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin. Infect. Dis. 73(11), e3606–e3614 (2021).
   PubMed Web of Science ®Google Scholar
• Bretagne S, Sitbon K, Botterel F et al. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first french pandemic wave. Microbiol. Spectr. 9(2), e0113821 (2021).
   PubMed Web of Science ®Google Scholar
• White PL, Dhillon R, Cordey A et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin. Infect. Dis. 73(7), e1634–e1644 (2021).
   PubMed Web of Science ®Google Scholar
• Prattes J, Wauters J, Giacobbe DR et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patientsa multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. 28(4), 580–587 (2022).
   PubMed Web of Science ®Google Scholar
• Koehler P, Bassetti M, Chakrabarti A et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 21(6), e149–e162 (2021).
   PubMed Web of Science ®Google Scholar
• Paramythiotou E, Dimopoulos G, Koliakos N et al. Epidemiology and incidence of COVID-19-associated pulmonary aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. Infect Dis. Ther. 10(3), 1779–1792 (2021).
   PubMed Web of Science ®Google Scholar
• Wasylyshyn AI, Wasylyshyn GR, Linder KA, Miceli MH. COVID-19-associated pulmonary aspergillosis at an academic medical center in the midwestern United States. Mycopathologia 186(4), 499–505 (2021).
   PubMed Web of Science ®Google Scholar
• Koehler P, Cornely OA, Kochanek M. Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis-a simulation study. Mycoses 64(1), 55–59 (2021).
   PubMed Web of Science ®Google Scholar
• Lormans P, Blot S, Amerlinck S, Devriendt Y, Dumoulin A. COVID-19 acquisition risk among ICU nursing staff with patient-driven use of aerosol-generating respiratory procedures and optimal use of personal protective equipment. Intensive Crit. Care Nurs. 63, 1029 (2021).
   Web of Science ®Google Scholar
• Er B, Er AG, Gülmez D et al. A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic. Mycoses 65(7), 724–732 (2022).
   PubMed Web of Science ®Google Scholar
• Armstrong-James D, Youngs J, Bicanic T et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur. Resp. J. 56(4), 2002554 (2020).
   PubMed Web of Science ®Google Scholar
• Dellière S, Dudoignon E, Fodil S et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin. Microbiol. Infect. 27(5), 790; e1–e5 (2020).
   PubMed Web of Science ®Google Scholar
• Culic O, Erakovic V, Cepelak I et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 450, 277; e89 (2002).
   PubMed Web of Science ®Google Scholar
• Latge J-P, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin. Microbiol. Rev. 33, 310; e75 (2019).
   Web of Science ®Google Scholar
• Dickson RP, Morris A. Macrolides, inflammation and the lung microbiome: untangling the web of causality. Thorax 72, 10; e2 (2017).
   PubMed Web of Science ®Google Scholar
• Nuffield Department of Population Health. RECOVERY: randomised Evaluation of COVID-19 Therapy. Available at: https://www.recoverytrial.net ( Accessed April 2024).
   Google Scholar
• Chong WH, Saha BK, Neu KP. Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection 50(1), 43–56 (2022).
   PubMed Web of Science ®Google Scholar
• Kim S-H, Hong JY, Bae S et al. Risk factors for coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis in critically ill patients: a nationwide, multicenter, retrospective cohort study. J. Korean Med. Sci. 37(18), e134 (2022).
   PubMed Web of Science ®Google Scholar
• van Grootveld R, van der Beek MT, Janssen NAF et al. CAPA2.0 study group. Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. J. Crit. Care 76, 154272 (2023).
   PubMed Web of Science ®Google Scholar
• Gangneux J-P, Dannaoui E, Fekkar A et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir. Med. 10(2), 180–190 (2022).
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285), 1637–1645 (2021).
   PubMed Web of Science ®Google Scholar
• Zia M, Goli M. Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article. J. Int. Med. Res. 49(9), 3000605211043413 (2021).
   Web of Science ®Google Scholar
• Apostolopoulou A, Garrigos ZE, Vijayvargiya P, Hope Lerner A, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. Diagnostics (Basel) 10(10), 807 (2020).
   PubMedGoogle Scholar
• Bulpa P, Duplaquet F, Dimopoulos G, Vogelaers D, Blot S. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations. Semin Respir. Crit. Care Med. 41(6), 851–861 (2020).
   PubMed Web of Science ®Google Scholar
• Feys S, Gonçalves SM, Khan M et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir. Med. 10(12), 1147–1159 S2213-2600(22)00259-4 (2022).
   PubMed Web of Science ®Google Scholar
• Koukaki E, Rovina N, Tzannis K et al. Fungal infections in the ICU during the COVID-19 era: descriptive and comparative analysis of 178 patients. J. Fungi. (Basel) 8(8), 881 (2022).
   PubMedGoogle Scholar
• Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. J. Fungi. (Basel) 6(3), 115 (2020).
   PubMedGoogle Scholar
• Cuenca-Estrella M, Kett DH, Wauters J. Defining standards of CARE for invasive fungal diseases in the ICU. J. Antimicrob. Chemother. 74(Suppl. 2), ii9–ii15 (2019).
   PubMedGoogle Scholar
• Dai Z, Cai M, Yao Y et al. Comparing the diagnostic value of bronchoalveolar lavage fluid galac-tomannan, serum galactomannanan, and serum 1,3-β-d-glucan in non-neutropenic respiratory disease patients with invasive pulmonary aspergillosis. Medicine (Baltimore) 100(14), e25233 (2021).
   PubMed Web of Science ®Google Scholar
• Mikulska M, Furfaro E, Dettori S et al. Aspergillus-PCR in bronchoalveolar lavage – diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. Mycoses 65(4), 411–418 (2022).
   PubMed Web of Science ®Google Scholar
• Schroeder M, Simon M, Katchanov J et al. Does galactomannan testing increase the diagnostic accuracy for IPA in the ICU? A prospective observational study. Crit. Care 20, 139 (2016).
   PubMed Web of Science ®Google Scholar
• Wahidi MM, Shojaee S, Lamb CR et al. The use of bronchoscopy during the coronavirus disease 2019 pandemic: CHEST/AABIP Guideline and Expert Panel Report. Chest 158, 1268–1281 (2020).
   PubMed Web of Science ®Google Scholar
• Rouzé A, Martin-Loeches I, Nseir S. COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection? Curr. Opin. Crit. Care 28(5), 470–479 (2022).
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs for antifungal agents. ( Accessed April 2024). ( Version 10.0). https://www.eucast.org
   Google Scholar
• Hong W, White PL, Backx M et al. CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis. Clin. Imaging 90, 11–18 (2022).
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Azoulay E, Kullberg BJ et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group. Clin. Infect. Dis. 72(Suppl. 2), S121–S127 (2021).
   PubMedGoogle Scholar
• Blot SI, Taccone FS, Van den Abeele AM et al. AspICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 186, 56–64 (2012).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Rijnders BJA, Brüggemann RJM et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 46(8), 1524–1535 (2020).
   PubMed Web of Science ®Google Scholar
• Lahmer T, Kriescher S, Herner A et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective Asp COVID-19 study. PLOS ONE 16(3), e0238825 (2021).
   PubMed Web of Science ®Google Scholar
• Hashim Z, Neyaz Z, Marak RSK, Nath A, Nityanand S, Tripathy NK. Practice guidelines for the diagnosis of COVID-19-associated pulmonary aspergillosis in an intensive care setting. J. Intensive Care Med. 37(8), 985–997 (2022).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 24(Suppl. 1), e1–e38 (2018).
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 63, e1–e60 (2016).
   PubMed Web of Science ®Google Scholar
• Levine M, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin. Transplant. 30(11), 1377–1386 (2016).
   PubMed Web of Science ®Google Scholar
• Verweij PE, Ananda-Rajah M, Andes D et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist. Updat. 21–22, 30–40 (2015).
   PubMed Web of Science ®Google Scholar
• Rutsaert L, Steinfort N, Van Hunsel T et al. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 10(1), 71 (2020).
   PubMed Web of Science ®Google Scholar
• Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin. Infect. Dis. 68, 1463–1471 (2019).
   PubMed Web of Science ®Google Scholar
• Abdul Salam ZH, Karlin RB, Ling ML, Yang KS. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am. J. Infect. Control 38(4), e1–e7 (2010).
   PubMed Web of Science ®Google Scholar
• Wang J, Yang L, Wang H, Wang L. Application of microfluidic chips in the detection of airborne microorganisms. Micromachines (Basel) 13(10), 1576 (2022).
   PubMed Web of Science ®Google Scholar
• Kanesaka I, Katsuse AK, Takahashi H, Kobayashi I. Evaluation of a bipolar ionization device in inactivation of antimicrobial-resistant bacteria, yeast, Aspergillus spp. and human coronavirus. J. Hosp. Infect. 126, 16–20 (2022).
   PubMed Web of Science ®Google Scholar
• Hatzl S, Reisinger AC, Posch F et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit. Care 25, 335 (2021).
   PubMed Web of Science ®Google Scholar
• Vanderbeke L, Jansen NAF, Bergmans DCJJ et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 47(6), 674–686 (2021).
   PubMed Web of Science ®Google Scholar
• Van Ackerbroeck S, Rutsaert L, Roelant E, Dillen K, Wauters J, Van Regenmortel N. Inhaled liposomal amphotericin B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis. Crit. Care 25(1), 298 (2021).
   PubMed Web of Science ®Google Scholar
• Soriano MC, Narvaez-Chavez G, Lopez-Olivencia M, Fortún J, de Pablo R. Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive aspergillosis. Intensive Care Med. 48(3), 360–361 (2022).
   PubMed Web of Science ®Google Scholar
• Reid G, Lynch JP, Fishbein MC, Clark NM. Mucormycosis. Semin Respir. Crit. Care Med. 41(1), 99–114 (2020).
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin. Infect. Dis. 54(Suppl. 1), S16–S22 (2012).
   PubMed Web of Science ®Google Scholar
• Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin. Microb. Rev. 13(2), 236–301 (2000).
   PubMed Web of Science ®Google Scholar
• Arthanari KK, Annamalai S, Thangavelu A, Palanivelu C, Suresh G, Anbuselvan S. Mucormycosis during coronavirus disease pandemic: a diagnosis we cannot afford to miss. J. Pharm. Bioallied. Sci. 13(Suppl. 2), S1769–S1771 (2021).
   PubMedGoogle Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 19(12), e405–e421 (2019).
   PubMed Web of Science ®Google Scholar
• Syed-Abdul S, Babu AS, Bellamkonda RS et al. Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors: an experience from a public hospital in India. J. Infect. 84(3), 351–354 (2021).
   PubMed Web of Science ®Google Scholar
• Dravid A, Kashiva R, Khan Z et al. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: a single center experience from Pune, Western India. Mycoses 65(5), 526–540 (2022).
   PubMed Web of Science ®Google Scholar
• Almyroudi MP, Akinosoglou K, Rello J, Blot S, Dimopoulos G. Clinical phenotypes of COVID-19 associated mucormycosis (CAM): a comprehensive review. Diagnostics (Basel) 12(12), 3092 (2022).
   PubMedGoogle Scholar
• Rubino F, Amiel SA, Zimmet P et al. New-onset diabetes in covid-19. N. Engl. J. Med. 383(8), 789–790 (2020).
   PubMed Web of Science ®Google Scholar
• Perricone C, Bartoloni E, Bursi R et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol. Res. 68, 213–224 (2020).
   PubMed Web of Science ®Google Scholar
• Kumar HM, Sharma P, Rudramurthy SM et al. Serum iron indices in COVID-19-associated mucormycosis: a case-control study. Mycoses 65(1), 120–127 (2022).
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 25(1), 26–34 (2019).
   PubMed Web of Science ®Google Scholar
• Nair AG, Adulkar NG, D'Cunha L et al. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Orbit 40(6), 499–504 (2021).
   PubMed Web of Science ®Google Scholar
• Sen M, Honavar SG, Bansal R et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J. Ophthalmol. 69(7), 1670–1692 (2021).
   PubMed Web of Science ®Google Scholar
• Meshram HS, Kute VB, Yadav DK et al. Impact of COVID-19-associated mucormycosis in kidney transplant recipients: a multicenter cohort study. Transplant Direct 8(1), e1255 (2021).
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Chen SC, Kauffman CA et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin. Infect. Dis. 71, 1367–1376 (2020).
   PubMed Web of Science ®Google Scholar
• Danion F, Letscher-Bru V, Guitard J et al. Coronavirus disease 2019-associated mucormycosis in France: a rare but deadly complication. Open Forum Infect Dis. 9(2), ofab566 (2021).
   PubMed Web of Science ®Google Scholar
• Pruthi H, Muthu V, Bhujade H et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia 22, 1–7 (2021).
   Google Scholar
• Philip AC, Madan P, Sharma S, Das S. Utility of MGG and Papanicolaou stained smears in the detection of mucormycosis in nasal swab/scraping/biopsy samples of COVID 19 patients. Diagn. Cytopathol. 50(3), 93–98 (2022).
   PubMed Web of Science ®Google Scholar
• Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol. 56, S93 (2018).
   PubMed Web of Science ®Google Scholar
• Skiada A, Pavleas I, Dragari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J. Fungi. (Basel) 6(4), 265 (2020).
   PubMedGoogle Scholar
• Dadwal SS, Kontoyiannis DP. Recent advances in molecular diagnosis of mucormycosis. Expert Rev. Mol. Diagn. 18, 845–854 (2018).
   PubMed Web of Science ®Google Scholar
• Schwarz P, Guedouar H, Laouiti F, Grenouillet F, Dannaoui E. Identification of mucorales by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J. Fungi. 5, 56 (2019).
   Web of Science ®Google Scholar
• Rudramurthy SM, Hoenigl M, Meis JD et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 64(9), 1028–1037 (2021).
   PubMed Web of Science ®Google Scholar
• Yadav T, Tiwari S, Gupta A et al. Magnetic resonance imaging in coronavirus disease – 2019 associated rhino-orbital-cerebral mucormycosis (CA-ROCM) – imaging analysis of 50 consecutive patients. Curr. Probl. Diagn. Radiol. 51(1), 112–120 (2022).
   PubMed Web of Science ®Google Scholar
• Garg M, Prabhakar N, Muthu V et al. CT findings of COVID-19-associated pulmonary mucormycosis: a case series and literature review. Radiology 302(1), 214–217 (2022).
   PubMed Web of Science ®Google Scholar
• Ashraf DC, Idowu OO, Hirabayashi KE et al. Outcomes of a modified treatment ladder algorithm using retrobulbar amphotericin b for invasive fungal rhino-orbital sinusitis. Am. J. Ophthalmol. 237, 299–309 S0002-9394(21)00319-316 (2021).
   PubMed Web of Science ®Google Scholar
• Ish P, Ish S. Prevention of mucormycosis in COVID-19 – the need of the hour. Indian J. Ophthalmol. 69(7), 1969 (2021).
   PubMed Web of Science ®Google Scholar
• Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J. Ophthalmol. 69, 1361–1365 (2021).
   PubMed Web of Science ®Google Scholar
• Mah J, Nicholas V, Tayyar R et al. Superior accuracy of aspergillus plasma cell-free DNA polymerase chain reaction over serum galactomannan for the diagnosis of invasive aspergillosis. Clin. Infect. Dis. 77(9), 1282–1290 (2023).
   PubMed Web of Science ®Google Scholar
• Kriegl L, Havlicek V, Dichtl K, Egger M, Hoenigl M. Siderophores: a potential role as a diagnostic for invasive fungal disease. Curr. Opin. Infect Dis. 35(6), 485–492 (2022).
   PubMed Web of Science ®Google Scholar